BiotechTube

Copanlisib + Nivolumab

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor

Conditions

Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer

Trial Timeline

Jan 17, 2019 → Jun 30, 2025

NCT ID
NCT03711058

About Copanlisib + Nivolumab

Copanlisib + Nivolumab is a phase 1/2 stage product being developed by Bristol Myers Squibb for Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT03711058. Target conditions include Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer.

What happened to similar drugs?

1 of 20 similar drugs in Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor were approved

Approved (1) Terminated (1) Active (18)
✅DurvalumabAstraZenecaApproved
🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
🔄zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
🔄Nivolumab + EverolimusOno PharmaceuticalPhase 3
🔄SHR-1210 + Apatinib + SorafenibJiangsu Hengrui MedicinePhase 3
🔄SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811Jiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03711058Phase 1/2Completed

Competing Products

20 competing products in Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
33
PLX3397 + vemurafenibDaiichi SankyoPhase 1
21
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
26
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44
zolbetuximabAstellas PharmaPre-clinical
33
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
ASP1948Astellas PharmaPhase 1
29
LenvatinibEisaiPhase 2
35
LenvatinibEisaiPhase 1
29
Nivolumab + EverolimusOno PharmaceuticalPhase 3
40
ONO-7913 + ONO-4538 + Fluorouracil + Oxaliplatin + Levofolinate + Bevacizumab + CetuximabOno PharmaceuticalPhase 1
33
SHR-4602Jiangsu Hengrui MedicinePhase 2
42
SHR-1210 + Apatinib + SorafenibJiangsu Hengrui MedicinePhase 3
40
HRS-6209 in Combination with Fulvestrant + HRS-6209 in Combination with HRS-1358 + HRS-6209 in Combination with Letrozole + HRS-6209 in Combination with HRS-8080 + HRS-6209 in Combination with HRS-1358Jiangsu Hengrui MedicinePhase 1/2
39
Camrelizumab + HAIC + TKIJiangsu Hengrui MedicinePhase 2
31
SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811Jiangsu Hengrui MedicinePhase 3
44
Telisotuzumab Adizutecan + Budigalimab + Fluorouracil + Leucovorin + OxaliplatinAbbViePhase 2
42